Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are tied to a reduction in alcohol intake, according to a research ...

Children who are living with severe obesity are more likely to experience a clinically relevant change in BMI when GLP-1 ...

Liraglutide and semaglutide reduce alcohol intake, cutting it by nearly two-thirds within four months of treatment.

Researchers used data-driven clustering to define 6 distinct obesity subtypes, offering a potential paradigm shift in how ...

News Evidence That GLP-1 Drugs Achieve Weight Loss Primarily by Reducing Fat Mass More Than Muscle. Diabetes and obesity have become pressing health issues worldwide. Glucagon-lik ...

GLP-1 receptor agonists are reshaping obesity care. OHE highlights access challenges, prescribing policy, and how patient and ...

You may have heard of "Ozempic face" and "Ozempic butt." Well, now there's "Ozempic mouth" and "Ozempic feet" to describe ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can lead to significant weight loss and improve blood sugar control in adults with severe mental illness, as well as having positive effects on ...

First-generation GLP-1 weight-loss drugs can help reduce the risk of obesity-related cancers, new research shows. Liraglutide ...

Landmark research suggests the appetite-suppressing jabs which mimic a hormone that makes us feel full also significantly cut ...